Pharmaceuticals & Biopharmaceuticals

Toronto – September 14, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) will hold a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT.

Cardiol schedules investor session at Lotte New York Palace Hotel

The session takes place in the Louis Room on the fourth floor of the venue. A live webcast will be available under the Events & Presentations section of the company's investor website.

Company advances Phase III trial for recurrent pericarditis treatment

Cardiol's lead candidate, CardiolRx, is being evaluated in the pivotal Phase III MAVERIC trial (NCT06708299) for recurrent pericarditis, following the completed Phase II MAvERIC-Pilot study (NCT05494788). The U.S. FDA has granted Orphan Drug Designation to CardiolRx for pericarditis, including the recurrent form of the disease.

Sydney – September 14, 2026 -- Kazia Therapeutics Limited (NASDAQ: KZIA) has dosed the first patient in Arm A of PNOC035, a Phase 2 platform study testing paxalisib combined with gemcitabine for recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT), an aggressive pediatric brain cancer with no approved therapies.

Preclinical data showed the combination nearly quadrupled median survival in an AT/RT model

In an orthotopic AT/RT preclinical model, the paxalisib-gemcitabine combination extended median survival from 22 to 82.5 days (p0.0001) and showed complementary anti-tumor activity across multiple AT/RT cell lines. These findings, previously presented at ISPNO, AACR and Neuro-Oncology meetings, formed the scientific basis for advancing into the multicenter PNOC035 trial.

Ramat Gan, Israel – September 13, 2026 -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) will rebrand as Eocene Ltd. and begin trading under the ticker EOCN on the Nasdaq Capital Market starting September 10, 2026, after terminating its $20 million standby equity purchase agreement with Yorkville and regaining compliance with Nasdaq's minimum bid price rule.

Company terminates $20 million Yorkville equity facility after raising $7.3 million

Galmed terminated its Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville), effective September 8, 2026. The facility had provided up to $20 million in equity financing; the company raised approximately $7.3 million through the issuance of 437,947 ordinary shares before termination.

College Station, Texas – September 13, 2026 -- Matica Biotechnology, a Texas-based cell and gene therapy CDMO, has entered a collaboration with Bondwell Technologies to advance the latter's proprietary protein bioprocessing platform toward manufacturing readiness.

Matica Bio will provide development expertise to prepare Bondwell's technology for commercialization

Under the agreement, Matica Bio will support Bondwell Technologies, headquartered in College Station, in scaling its proprietary protein technology for bioprocessing and life science applications. The collaboration is designed to move Bondwell's platform closer to manufacturing readiness and future commercial deployment.

Cambridge, Mass. – September 13, 2026 -- Marengo Therapeutics has completed enrollment in the monotherapy cohorts of its Phase 1/2 STARt-001 trial evaluating invikafusp alfa across eight distinct PD-1-resistant tumor types, with updated results selected for an oral presentation at the ESMO 2026 Congress in Madrid, October 23-27.

Trial enrollment closes across eight PD-1-resistant tumor types

The monotherapy cohorts covered patients with MSS colorectal cancer, PD-L1-negative non-small cell lung cancer and triple-negative breast cancer, among others resistant to checkpoint blockade. Enrollment continues in standard-of-care combination cohorts, while the company plans to name lead indications for focused development alongside the ESMO data release.

Dallas – September 13, 2026 -- The U.S. Food and Drug Administration has accepted and filed the Biologics License Application for MOGENRY, an optogenetic gene therapy from Nanoscope Therapeutics designed to restore vision in retinitis pigmentosa patients with severe vision loss. If approved, MOGENRY would become the first gene-agnostic treatment available for this patient population, which currently has no approved therapy.

RESTORE trial data anchors the regulatory filing

The BLA is supported by the Phase 2b/3 RESTORE trial (NCT04945772), a multicenter, randomized, double-masked, sham-controlled study that met its primary and key secondary endpoints, showing improvements in visual acuity at weeks 52 and 76. No treatment-related serious adverse events were reported. Additional efficacy and safety data come from the earlier Phase 1/2a trial (NCT04919473).

Wellesley Hills, Mass. – – September 13, 2026 -- Cure Alzheimer's Fund (CureAlz) has appointed Drs. Michelle Arkin, Ronald B. DeMattos, Donna M. Huryn, and Kalpana Merchant to its Scientific Advisory Board (SAB), adding decades of pharmaceutical drug-discovery experience to the nonprofit's research-funding strategy.

Board addition brings direct experience from an FDA-cleared Alzheimer's drug

Ronald B. DeMattos spent more than 20 years in neuroscience discovery at Eli Lilly, most recently as Senior Vice President and Chief Scientific Officer for Neurobiologics, where he led development of candidates that advanced to clinical studies including donanemab, the FDA-cleared amyloid-lowering antibody marketed as Kisunla for early Alzheimer's disease.

Shanghai – September 13, 2026 -- Natural Field has expanded its NF TriSolve® nutraceutical solutions platform into the sleep wellness category with the launch of NF TriSolve® SleepRestore Complex, targeting a growing segment of the global nutrition market.

Natural Field enters sleep wellness with a multi-component nutraceutical formulation

The NF TriSolve® SleepRestore Complex combines multiple functional components into a coordinated formulation designed for sleep-focused nutraceutical applications. The launch marks Natural Field's first entry into the sleep wellness market under its branded NF TriSolve® platform, which converts ingredient expertise, scientific research and formulation capabilities into targeted wellness solutions for global nutrition brands.

Carmiel, Israel – September 13, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) confirmed that Chief Financial Officer Gilad Mamlok will represent the company at two investor conferences in New York City this month.

Mamlok addresses H.C. Wainwright's 28th Annual Global Investment Conference on September 14

The presentation is scheduled for 2:00 p.m. EDT during the three-day event running September 14-16, 2026.

Morgan Stanley's 24th Annual Global Healthcare Conference hosts a fireside chat on September 16

The session is set for 1:05 p.m. EDT and will be streamed via a live audio webcast, with an archived replay available afterward on Protalix's investor relations site.

Taipei – September 13, 2026 -- HanchorBio Inc. (TWSE: 7827) said the U.S. Food and Drug Administration has cleared its HCB101 Single-Patient Expanded Access Protocol (HCB101-EA-001) as "safe to proceed," allowing a Phase 1 patient who showed clinical benefit to continue receiving the investigational drug beyond the parent trial.

FDA authorizes continued treatment for a single Phase 1 patient

The clearance permits the patient to keep receiving HCB101 outside the standard clinical trial structure under the FDA's Expanded Access, or compassionate use, framework. The agency's review weighed the patient's clinical circumstances, including whether the potential benefit justified the risks given the severity of the disease. HanchorBio noted the determination applies only to this individual-patient protocol and does not constitute approval of HCB101 or an FDA finding on its broader safety or efficacy.